About UsTherapeutic AreasNews & InsightsTeamPartnership
Contact

Leading health innovations. Impacting the world.

Sapphire Pharma Inc. is a global pharmaceutical company dedicated to developing and providing access to therapies for patients with infectious diseases, autoimmune conditions and women’s health issues.

About Us

Improve access and affordability to essential medicines

We are committed to advancing medical innovation, developing affordable medicines, and fostering strategic partnerships that allow us to broaden access to medicine at scale. By redefining the development, manufacturing and distribution processes we can deliver impact to patients who are suffering from malaria, systemic lupus erythematosus, rheumatoid arthritis and beyond.
Therapeutic Areas

Malaria

Lupus

Rheumatoid Arthritis

Therapeutic Areas

0
1
2
3
01

Malaria

Human malaria is caused by protozoan parasites of the genus Plasmodium, including five species: P. falciparum, P. vivax, P. ovale, P. malariae, and the emerging P. knowlesi. Most malaria deaths are due to P. falciparum. Infection occurs mainly through the bite of a female Anopheles mosquito. In 2023, there were an estimated 263 million cases and 597,000 deaths globally, with the African Region accounting for 94% of cases and 95% of deaths. The global incidence rate was 60.4 cases per 1,000 people at risk.

02

Lupus

Systemic lupus erythematosus (SLE) is an autoimmune disorder marked by flare-ups and remission and can cause damage to organs such as the kidneys, nervous system, joints, and skin. It is estimated that about 90% of individuals with SLE are women. SLE is more common in African American women compared to Caucasians, and it is also found to be more common in Hispanics and Asians. Around 20% of patients may develop discoid lupus erythematosus, which causes lesions on the face, ears, and scalp.

03

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammatory arthritis that predominantly affects the joints. Although all joints can be impacted, preferably the joints of hands, feet and knees are affected by RA. Without proper treatment, RA leads to irreversible damage to the joint structures and is frequently associated with damage to multiple organs. Studies have shown that women are two to three times more likely to develop RA than men.

News & Insights

Press
Jan 19

Sapphire Pharma Chairman & CEO Ramu Veerappan to Speak at World Economic Forum 2025

Press
Jan 16

Addressing a Global Crisis: Sapphire Pharma’s Mission to Improve Access to Life-Saving Medicines

Company News
Jan 15

Sapphire Pharma will be attending the World Economic Forum 2025 in Davos, where global leaders converge to shape a healthier, more equitable future.

Resources
Jan 14

Filling the Gap: Addressing Unmet Needs in Malaria Control

View all

Our Team

Leadership

Ramu Veerappan
Chairman and Chief Executive Officer

Ramu Veerappan is a passionate and visionary entrepreneur with over two decades of consulting experience in pharmaceuticals, biotechnology, and medical devices. He served earlier as President of Mtech Consulting Group, working with clients like Sanofi, Pfizer, and Merck, and also the Founder & Principal of Tydings Capital LLC, a venture capital firm investing in technology, healthcare, and financial services.

Luis Restrepo
Chief Financial Officer

Luis F. Restrepo is a seasoned entrepreneur and finance expert with over 30 years of experience across consumer goods, securities trading, investment banking, and technology. He co-founded and managed four startups, including a pharmaceutical firm and a quasi-medical devices company, and led market expansions for major firms like Procter & Gamble and Religare Capital Markets

Robert Poorvin
Chief Technology Officer

Rob Poorvin is a clinical trials expert with 35 years of experience, contributing to nearly 100 global drug, device, and vaccine submissions. He has worked at Merck, Medidata, Sanofi, ClinPro (formerly DZS), as well as startups and hospitals. Passionate about innovation, Rob pioneers technologies like FHIR to streamline EHR-to-EDC pipelines, improving patient outcomes.

Prakash Packiaswamynathan
Head of Global Research

Prakash has nearly three decades of experience in entrepreneurship development and training, creating skill programs for aspiring entrepreneurs and mentoring small business owners across diverse sectors like retail, logistics, and healthcare. He has held significant roles in India’s premier Science Park and a university’s Entrepreneurship Development Cell.

Advisory Board

John D. Carter, MD
Scientific and Medical Advisor

A nationally renowned rheumatologist, Dr. Carter previously worked as a Professor of Medicine and Chief of the Division of Rheumatology at the University of South Florida Morsani College of Medicine. Starting in 2001, he quickly rose through the ranks to become the Chief of Rheumatology in 2007 and full professor in 2014. He recently left USF to open his private practice. He has published over 100 peer-reviewed articles, book chapters and abstracts. He has vast clinical experience with hydroxychloroquine and many of his publications detail the safety and tremendous efficacy of this medication.

Dipan B. Ray, M. Pharm, MS, PhD, Rph
Scientific and Medical Advisor

For over 16 years, Dipan led the Experiential Education Department at Touro College of Pharmacy in New York where he established affiliations with major institutions serving diverse patient populations. He worked on global public health and academic development projects with national and international colleagues, some of which were published as abstracts and peer-reviewed journal articles. With over thirty years of experience in community pharmacy practice, Dipan has been able to share his learnings with students on effective communication with culturally diverse patient populations

Building together for future success.

We focus on creating innovative solutions that maximize impact for patients, particularly in terms of access and affordability. By building strong partnerships with leading experts and taking a forward-looking approach to collaboration, we aim to drive the progress of our pipeline both now and in the future.

Contact
© 2025 Sapphire Pharma. All rights reserved.
info@sapphirepharma.us
216 Stelton Road, Suite A-1, Piscataway, NJ 08854 USA